JP2003506414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506414A5 JP2003506414A5 JP2001514977A JP2001514977A JP2003506414A5 JP 2003506414 A5 JP2003506414 A5 JP 2003506414A5 JP 2001514977 A JP2001514977 A JP 2001514977A JP 2001514977 A JP2001514977 A JP 2001514977A JP 2003506414 A5 JP2003506414 A5 JP 2003506414A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- stated
- pharmaceutical composition
- bone marrow
- nhl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 210000001185 bone marrow Anatomy 0.000 description 20
- 238000001764 infiltration Methods 0.000 description 19
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 17
- 230000008595 infiltration Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000779 depleting effect Effects 0.000 description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14828899P | 1999-08-11 | 1999-08-11 | |
| US60/148,288 | 1999-08-11 | ||
| US09/625,856 | 2000-07-26 | ||
| US09/625,856 US6451284B1 (en) | 1999-08-11 | 2000-07-26 | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| PCT/US2000/020733 WO2001010461A1 (en) | 1999-08-11 | 2000-07-31 | New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003506414A JP2003506414A (ja) | 2003-02-18 |
| JP2003506414A5 true JP2003506414A5 (https=) | 2007-10-04 |
| JP4662672B2 JP4662672B2 (ja) | 2011-03-30 |
Family
ID=26845721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001514977A Expired - Lifetime JP4662672B2 (ja) | 1999-08-11 | 2000-07-31 | 放射性免疫療法に先立つ血液学的毒性測定のための新規な臨床検査指標 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US6451284B1 (https=) |
| EP (1) | EP1207904B1 (https=) |
| JP (1) | JP4662672B2 (https=) |
| CN (2) | CN100540053C (https=) |
| AT (1) | ATE387915T1 (https=) |
| AU (2) | AU780222B2 (https=) |
| CA (1) | CA2378584C (https=) |
| CY (1) | CY1108118T1 (https=) |
| DE (1) | DE60038239T2 (https=) |
| DK (1) | DK1207904T3 (https=) |
| ES (1) | ES2302698T3 (https=) |
| MX (1) | MXPA02001403A (https=) |
| MY (1) | MY135734A (https=) |
| NO (1) | NO329592B1 (https=) |
| PT (1) | PT1207904E (https=) |
| TW (1) | TWI317284B (https=) |
| WO (1) | WO2001010461A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011279A (es) | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| CN100389825C (zh) * | 1999-08-11 | 2008-05-28 | 拜奥根Idec公司 | 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者 |
| US6451284B1 (en) * | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| CA2411102A1 (en) * | 2000-06-20 | 2001-12-27 | Idec Pharmaceutical Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| IL157946A0 (en) * | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| EP2062916A3 (en) | 2003-04-09 | 2009-08-19 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor |
| CA2525251C (en) * | 2003-05-09 | 2015-10-27 | Duke University | Cd20-specific antibodies and methods employing same |
| PL1631313T3 (pl) | 2003-06-05 | 2015-08-31 | Genentech Inc | Terapia skojarzona zaburzeń z komórek B |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005117848A2 (en) | 2004-06-02 | 2005-12-15 | Sidney Kimmel Cancer Center | Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| TW201422238A (zh) | 2004-06-04 | 2014-06-16 | Genentech Inc | Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品 |
| ATE460672T1 (de) | 2005-05-20 | 2010-03-15 | Genentech Inc | Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit |
| JP2009502936A (ja) | 2005-07-25 | 2009-01-29 | トルビオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２０特異的結合分子の単一投与量 |
| HRP20140338T1 (hr) | 2005-07-25 | 2014-06-20 | Emergent Product Development Seattle, Llc | Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20 |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| KR101456728B1 (ko) * | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
| EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| CN104059955A (zh) | 2009-08-11 | 2014-09-24 | 弗·哈夫曼-拉罗切有限公司 | 在无谷氨酰胺的细胞培养基中的蛋白质生产 |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| CA3036385C (en) * | 2013-12-17 | 2022-06-21 | Alentic Microscience Inc. | Dosimeters including lensless imaging systems |
| AU2016271124C1 (en) | 2015-05-30 | 2020-05-14 | Molecular Templates, Inc. | De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| MX391086B (es) | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| EP3352760B1 (en) | 2015-09-21 | 2026-03-11 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| NZ741067A (en) | 2015-10-02 | 2023-07-28 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
| EP3714937A1 (en) * | 2019-03-28 | 2020-09-30 | Koninklijke Philips N.V. | Determining hematologic toxicity risk following radiotherapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242679A (en) * | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5591632A (en) * | 1987-03-02 | 1997-01-07 | Beth Israel Hospital | Recombinant BCG |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| JPH06501705A (ja) | 1990-11-05 | 1994-02-24 | ブリストル−マイアーズ スクイブ カンパニー | 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療 |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| ES2251723T3 (es) | 1994-08-12 | 2006-05-01 | Immunomedics, Inc. | Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia. |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US5843436A (en) * | 1996-04-22 | 1998-12-01 | The Trustees Of Columbia University, In The City Of New York | Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci |
| US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| CA2340091C (en) * | 1998-08-11 | 2013-02-05 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| MXPA01011279A (es) | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| CA2375912C (en) | 1999-06-09 | 2014-03-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| US6451284B1 (en) * | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| CA2422076A1 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
-
2000
- 2000-07-26 US US09/625,856 patent/US6451284B1/en not_active Expired - Lifetime
- 2000-07-31 EP EP00959150A patent/EP1207904B1/en not_active Expired - Lifetime
- 2000-07-31 JP JP2001514977A patent/JP4662672B2/ja not_active Expired - Lifetime
- 2000-07-31 CN CNB008124426A patent/CN100540053C/zh not_active Expired - Lifetime
- 2000-07-31 MX MXPA02001403A patent/MXPA02001403A/es active IP Right Grant
- 2000-07-31 CN CNA2004100590274A patent/CN1596985A/zh active Pending
- 2000-07-31 DK DK00959150T patent/DK1207904T3/da active
- 2000-07-31 ES ES00959150T patent/ES2302698T3/es not_active Expired - Lifetime
- 2000-07-31 AT AT00959150T patent/ATE387915T1/de active
- 2000-07-31 CA CA2378584A patent/CA2378584C/en not_active Expired - Lifetime
- 2000-07-31 DE DE60038239T patent/DE60038239T2/de not_active Expired - Lifetime
- 2000-07-31 WO PCT/US2000/020733 patent/WO2001010461A1/en not_active Ceased
- 2000-07-31 PT PT00959150T patent/PT1207904E/pt unknown
- 2000-07-31 AU AU70521/00A patent/AU780222B2/en not_active Expired
- 2000-08-04 MY MYPI20003577A patent/MY135734A/en unknown
- 2000-08-11 TW TW089116242A patent/TWI317284B/zh not_active IP Right Cessation
-
2002
- 2002-02-08 NO NO20020637A patent/NO329592B1/no not_active IP Right Cessation
- 2002-07-16 US US10/195,426 patent/US7195750B2/en not_active Expired - Lifetime
-
2005
- 2005-06-10 AU AU2005202560A patent/AU2005202560B2/en not_active Expired
-
2007
- 2007-02-27 US US11/679,687 patent/US20070148714A1/en not_active Abandoned
-
2008
- 2008-06-03 CY CY20081100584T patent/CY1108118T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003506414A5 (https=) | ||
| DE60038239T2 (de) | Neue klinische parameter zur bestimmung einer hämatologischen toxizität vor einer strahlenimmuntherapie | |
| Davis et al. | The radioisotope contributes significantly to the activity of radioimmunotherapy | |
| Lindén et al. | Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab | |
| JP2003513012A5 (https=) | ||
| Burke et al. | Radioimmunotherapy for acute leukemia | |
| JP2003506413A (ja) | 中間および高グレードの非ホジキンリンパ腫の抗−ｃｄ２０抗体による治療 | |
| JP2004512262A5 (https=) | ||
| AU7626000A (en) | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies | |
| Tuscano et al. | Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts | |
| Borghaei et al. | Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin) | |
| Jurcic | Targeted alpha-particle therapy for hematologic malignancies | |
| Witzig | Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin’s lymphoma | |
| Iagaru et al. | 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) therapy of low-grade refractory/relapsed Non-Hodgkin Lymphoma | |
| Illidge et al. | Radioimmunotherapy in follicular lymphoma | |
| Michel et al. | 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo | |
| Buchegger et al. | Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma | |
| Torres-García et al. | Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience | |
| Emmanouilides | Radioimmunotherapy for non-Hodgkin’s lymphoma | |
| Leonard et al. | Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma: HEMATOLOGY | |
| White | Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin®). | |
| William et al. | I-131 tositumomab | |
| Bailly et al. | Radioimmunotherapy of lymphomas | |
| Meredith et al. | Clinical development of radioimmunotherapy for B-cell non-Hodgkin’s lymphoma | |
| Petryk et al. | Hematologic malignancies |